Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Change in Receivables (2020 - 2025)

Maravai Lifesciences Holdings has reported Change in Receivables over the past 6 years, most recently at $3.0 million for Q4 2025.

  • Quarterly results put Change in Receivables at $3.0 million for Q4 2025, down 74.09% from a year ago — trailing twelve months through Dec 2025 was -$12.8 million (up 10.75% YoY), and the annual figure for FY2025 was -$12.8 million, up 10.75%.
  • Change in Receivables for Q4 2025 was $3.0 million at Maravai Lifesciences Holdings, up from -$5.1 million in the prior quarter.
  • Over the last five years, Change in Receivables for MRVI hit a ceiling of $70.8 million in Q1 2021 and a floor of -$82.4 million in Q1 2023.
  • Median Change in Receivables over the past 5 years was -$2.6 million (2023), compared with a mean of -$945350.0.
  • Peak annual rise in Change in Receivables hit 602.08% in 2021, while the deepest fall reached 9882.85% in 2021.
  • Maravai Lifesciences Holdings' Change in Receivables stood at $51.5 million in 2021, then tumbled by 49.99% to $25.8 million in 2022, then plummeted by 65.92% to $8.8 million in 2023, then surged by 30.11% to $11.4 million in 2024, then crashed by 74.09% to $3.0 million in 2025.
  • The last three reported values for Change in Receivables were $3.0 million (Q4 2025), -$5.1 million (Q3 2025), and -$501000.0 (Q2 2025) per Business Quant data.